Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
J Hepatobiliary Pancreat Sci. 2022 Jul;29(7):741-757. doi: 10.1002/jhbp.1045. Epub 2021 Sep 21.
Pancreatic cancer is one of the most aggressive diseases in the world due to a lack of early detection, leading to an overall 5-year survival of only 10%. In recent years, clinical trials targeted pancreatic cancer in efforts to improve survival. These studies introduce new technologies, concepts, and evidence which have instilled new optimism for improving prognosis. This review summarizes the current status of the recent (5-year) clinical trials and describes contemporary research on pancreatic cancer, including surgical technology, diagnostic skills, traditional chemoradiotherapy, neoadjuvant chemotherapy, immunotherapy, targeted therapy, and precision medicine. Then, the future trend and direction of clinical trials on pancreatic cancer are discussed.
胰腺癌是世界上侵袭性最强的疾病之一，由于缺乏早期检测，整体 5 年生存率仅为 10%。近年来，针对胰腺癌的临床试验旨在提高生存率。这些研究引入了新技术、新概念和新证据，为改善预后带来了新的希望。本综述总结了最近（5 年）临床试验的现状，并描述了胰腺癌的当代研究，包括手术技术、诊断技能、传统放化疗、新辅助化疗、免疫疗法、靶向治疗和精准医学。然后，讨论了胰腺癌临床试验的未来趋势和方向。
